NCT06065150

Brief Summary

For uncomplicated acute small bowel obstruction (aSBO), the "Bologna guidelines" recommend non-surgical management of 72 hours before considering surgery. This treatment is based on the placement of a nasogastric tube and the correction of hydro-electrolyte disorders. Non-surgical management is only effective in 60 to 70% and surgery is therefore necessary in 30 to 40% of cases after medical treatment for at least 3 days. This therefore leads to an increase in the length of hospital stay. Some authors also point out that postponing surgery for 3 days would aggravate the morbidity and mortality of surgery. Indeed, aSBO surgery has a complication rate of 10-40% and a mortality of up to 4%. There is a lack of studies evaluating what is the best management strategy for aSBO, especially with regard to the duration of medical treatment. Many recent studies plead in favor of early surgical treatment (\<24 hours) which would reduce the morbidity and mortality rate of surgery but also the overall cost of treatment by reducing the length of stay. This paradigm shift is linked to the improvement of anesthetic and intensive care management over the last few years, but also to the advent of laparoscopy in emergency surgery. Indeed, laparoscopy could reduce the duration of hospitalization but also the operative morbidity and mortality. However, this surgical approach is not feasible in all situations and the conversion rate is reported in 30 to 76% of cases. One of the factors favoring the feasibility of the laparoscopic approach is the performance of early surgery. Another parameter favoring the feasibility of the laparoscopic approach is the aSBO mechanism: an aSBO on flange (SBA) is more likely to be treated effectively by laparoscopic than an aSBO on multiple adhesions (MA). In the literature, there is little to differentiate SBAs from MAs. Advances in CT scans have made it possible to describe the signs associated with the SBA mechanism and then to propose a score making it possible to predict the SBA mechanism with good performance (sensitivity 67.6%, specificity 84.6%). This score not only has the advantage of predicting the mechanism of the occlusion but it also makes it possible to predict the failure of non-surgical treatment if the score is ≥5.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
630

participants targeted

Target at P75+ for not_applicable

Timeline
21mo left

Started Jan 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

14 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress57%
Jan 2024Jan 2028

First Submitted

Initial submission to the registry

September 13, 2023

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 3, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

January 30, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 29, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 29, 2028

Last Updated

June 13, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

September 13, 2023

Last Update Submit

June 12, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • 90-day morbidity and mortality of aSBO management using the radiological score

    The main objective is to evaluate the effectiveness, in terms of 90-day morbidity and mortality, of management of uncomplicated aSBO based on the use of the radiological score as a tool to select patients eligible for early surgery. compared to standard care (medical treatment for 72 hours).

    90 days

Secondary Outcomes (6)

  • Morbidity and mortality at 30 days

    30 days

  • Length of patient hospitalization

    assessed to 2 days

  • Recurrence rate of aSBO

    one year

  • Rate of recourse to surgery for patients not operated on straight away

    One year

  • Surgical morbidity and mortality at 30 days of patients operated on during the first hospitalization

    30 days

  • +1 more secondary outcomes

Study Arms (2)

Standard support

ACTIVE COMPARATOR

Initial medical treatment: placement of a nasogastric tube associated with hydration and vascular filling for hypovolaemic patients. Other medical treatments for occlusive small bowel syndrome on adhesion or flange can be performed but are not systematically recommended. Their use is left to the discretion of the surgeon. Medical treatment is carried out over 72 hours from admission. In case of resumption of a transit by gas and/or stools associated with a tolerance to the food, the exit is authorized without resorting to surgery. In the absence of a resumption of transit by gas and/or stools associated with tolerance to food, semi-urgent surgical management is proposed 72 hours from the start of management. In the event of deterioration of the clinical condition during hospitalization, urgent surgery will be proposed, according to the recommendations for use.

Procedure: Standard support

Early surgery proposed according to the radiological score

EXPERIMENTAL

Patients included in the experimental arm have treatment adapted to the radiological score. The radiological score described by Berge et al. (Berge et al. Eur J Trauma Emerg Surg 2021) is calculated after patient inclusion.

Procedure: Early surgery proposed according to the radiological score

Interventions

See arm/group descriptions

Standard support

* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary. * If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management.

Early surgery proposed according to the radiological score

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Admission for acute intestinal obstruction of the small intestine on adhesion or bridle
  • Confirmation of the aSBO by a scanner
  • Adult patient
  • Beneficiary of a social security scheme
  • Having signed an informed consent

You may not qualify if:

  • Indication for urgent surgery (small intestine ischemia, intestinal pain, defence, hemodynamic shock, etc.)
  • Pregnancy or breastfeeding
  • Poor understanding of the French language
  • Person deprived of liberty by judicial or administrative decision
  • Person undergoing psychiatric treatment under duress
  • Person subject to a legal protection measure
  • Person unable to express consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

University Hospital of Amiens

Amiens, 80054, France

NOT YET RECRUITING

University Hospital of Angers

Angers, 49933, France

RECRUITING

University Hospital of Brest

Brest, 29609, France

NOT YET RECRUITING

University Hospital of Tours

Chambray-lès-Tours, 37170, France

RECRUITING

Hospital of Haut Anjou

Château-Gontier, 53200, France

NOT YET RECRUITING

University Hospital of Dijon Bourgogne

Dijon, 21000, France

NOT YET RECRUITING

University Hospital of Grenoble-Alpes

Grenoble, 38043, France

RECRUITING

Hospital of Vendée

La Roche-sur-Yon, 85925, France

RECRUITING

University Hospital of Montpellier

Montpellier, 34295, France

NOT YET RECRUITING

University Hospital of Nantes

Nantes, 44093, France

NOT YET RECRUITING

University Hospital of Nice

Nice, 06000, France

NOT YET RECRUITING

University Hospital of Lyon

Pierre-Bénite, 69495, France

NOT YET RECRUITING

University Hospital of Rennes

Rennes, 35033, France

NOT YET RECRUITING

University Hospital of Strasbourg

Strasbourg, 67098, France

NOT YET RECRUITING

Study Officials

  • Cécile Jaglin-Grimonprez

    University hospital of Angers

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
non applicable
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Multicentre randomized open-label controlled trial
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2023

First Posted

October 3, 2023

Study Start

January 30, 2024

Primary Completion (Estimated)

January 29, 2027

Study Completion (Estimated)

January 29, 2028

Last Updated

June 13, 2024

Record last verified: 2024-06

Locations